Dissecting fibrosis: Therapeutic insights from the small-molecule toolbox

Nature Reviews Drug Discovery

Volumn 14, Issue 10, 2015, Pages 693-720

  Nanthakumar, Carmel B ^a   Hatley, Richard J D ^a   Lemma, Seble ^b   Gauldie, Jack ^c   Marshall, Richard P ^a   Macdonald, Simon J F ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRASENTAN; BARDOXOLONE METHYL; BARICITINIB; BOSENTAN; CORTICOSTEROID; DASATINIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELAFIBRANOR; F 351; GKT 137831; IMATINIB; LOSARTAN; MACITENTAN; NILOTINIB; NINTEDANIB; OMIPALISIB; PIOGLITAZONE; PIRFENIDONE; RAPAMYCIN; ROSIGLITAZONE; SAROGLITAZAR; SILDENAFIL; SORAFENIB; TANZISERTIB; TRANSFORMING GROWTH FACTOR BETA; TRIAMCINOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CELL DAMAGE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE MODEL; DRUG ACTIVITY; DRUG DEVELOPMENT; DRUG RESEARCH; DRUG TARGETING; END STAGE RENAL DISEASE; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROGENESIS; FIBROSING ALVEOLITIS; FIBROSIS; HUMAN; INFLAMMATION; KIDNEY FIBROSIS; LIVER FIBROSIS; LUNG FIBROSIS; MONOTHERAPY; MYOFIBROBLAST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); POLYPHARMACOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN FIBROSIS; TISSUE INJURY; TREATMENT OUTCOME; KIDNEY; LIVER CIRRHOSIS; PATHOLOGY; PULMONARY FIBROSIS;

DRUG DISCOVERY; FIBROSIS; HUMANS; KIDNEY; LIVER CIRRHOSIS; MYOFIBROBLASTS; OXIDATIVE STRESS; PULMONARY FIBROSIS;

EID: 84942981199     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4592     Document Type: Review

References (304)

1. Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z. & Oster, G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 174, 810-816 (2006).
2. Olson, A. L. et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am. J. Respir. Crit. Care Med. 176, 277-284 (2007).
3. Allison, M. Stromedix acquisition signals growing interest in fibrosis. Nat. Biotechnol. 30, 375-376 (2012).
4. King, T. E. Jr. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2083-2092 (2014).
5. Datta, A., Scotton, C. J. & Chambers, R. C. Novel therapeutic approaches for pulmonary fibrosis. Br. J. Pharmacol. 163, 141-172 (2011).
6. Winstone, T. et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 13, 2626 (2014).
7. Kim, D. Interstitial lung disease in rheumatoid arthritis: recent advances. Curr. Opin. Pulm. Med. 12, 346-353 (2006).
8. Hart, S. P. Understanding CT patterns in idiopathic pulmonary fibrosis. Lancet Respir. Med. 2, 249-250 (2014).
9. Hosenpud, J. D., Bennett, L. E., Keck, B. M., Edwards, E. B. & Novick, R. J. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 351, 24-27 (1998).
10. Raghu, G., Anstrom, K. J., King, T. E. Jr., Lasky, J. A. & Martinez, F. J. Prednisone, azathioprine and N acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 366, 1968-1977 (2012).
11. Sharma, K. et al. Pirfenidone for diabetic nephropathy. J. Am. Soc. Nephrol. 22, 1144-1151 (2011).
12. Ma, Z. et al. Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents. Bioorg. Med. Chem. Lett. 24, 220-223 (2014).
13. Remuzzi, G., Schieppati, A. & Ruggenenti, P. Nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 346, 1145-1151 (2002).
14. Meguid El Nahas, A. & Bello, A. K. Chronic kidney disease: the global challenge. Lancet 365, 331-340 (2005).
15. Parving, H., Persson, F., Lewis, J. B., Lewis, E. J. & Hollenberg, N. K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446 (2008).
16. Colmenero, J. et al. Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G726-G734 (2009).
17. Talmadge, E. et al. A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 184, 92-99 (2011).
18. Schuppan, D. & Afdhal, N. H. Liver cirrhosis. Lancet 371, 838-851 (2008).
19. Ud Din, S. & Bayat, A. Strategic management of keloid disease in ethnic skin: a structured approach supported by emerging literature. Br. J. Dermatol. 169, 71-81 (2013).
20. Zurbig, P. et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 61, 3304-3313 (2012).
21. Maher, T. M. et al. Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 182, 73-82 (2010).
22. Jin, Y. et al. A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nat. Med. 18, 580-589 (2012).
23. Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178-196 (2014).
24. Konigshoff, M. et al. Functional Wnt signalling is increased in idiopathic pulmonary fibrosis. PLoS ONE 3, e2142 (2008).
25. LeBleu, V. S. et al. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 19, 1047-1054 (2013).
26. Humphreys, B. D. et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85-97 (2010).
27. Rock, J. R. et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc. Natl Acad. Sci. USA 108, E1475-E1483 (2011).
28. The idiopathic pulmonary fibrosis clinical research network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2093-2101 (2014).
29. De Zeeuw, D. et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 369, 2492-2503 (2013).
30. Mitani, Y. et al. Superoxide scavenging activity of pirfenidone-iron complex. Biochem. Biophys. Res. Commun. 372, 19-23 (2008).
31. Selman, M. et al. Colchicine, D penicillamine and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 114, 507-512 (1998).
32. Collard, H. R. et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 125, 2169-2174 (2004).
33. Ud Din, S., Bowring, A., Derbyshire, A., Morris, J. & Bayat, A. Identification of steroid sensitive responders versus non-responders in the treatment of keloid disease. Arch. Dermatol. Res. 305, 423-432 (2013).
34. Sidhu, S. S. et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE Trial). Dig. Dis. Sci. 57, 1664-1674 (2012).
35. Jackson, H. et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology 46, 1131-1137 (2007).
36. Seki, E. et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J. Clin. Invest. 119, 1858-1870 (2009).
37. Seki, E. et al. CCR2 promotes hepatic fibrosis in mice. Hepatology 50, 185-197 (2009).
38. Nicholson, A. G. et al. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 166, 173-177 (2002).
39. Xia, H. et al. Identification of a cell of origin for fibroblasts comprising the fibrotic reticulum in idiopathic pulmonary fibrosis. Am. J. Pathol. 184, 1369-1383 (2014).
40. Andersson-Sjoland, A. et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int. J. Biochem. Cell Biol. 40, 2129-2140 (2008).
41. Hung, C. et al. Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 188, 820-830 (2013).
42. Friedman, S. L. Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655-1669 (2008).
43. Keerthisingam, C. B. et al. Cyclooxygenase 2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-β in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am. J. Pathol. 158, 1411-1422 (2001).
44. Shi-Wen, X. et al. Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. Arthritis Rheum. 40, 1237-1244 (1997).
45. Tuan, T.-L. et al. Adenoviral overexpression and small interfering RNA suppression demonstrate that plasminogen activator inhibitor 1 produces elevated collagen accumulation in normal and keloid fibroblasts. Am. J. Pathol. 173, 1311-1325 (2008).
46. Huang, S. K. et al. Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice. Am. J. Pathol. 177, 2245-2255 (2010).
47. Bechtel, W. et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat. Med. 16, 544-550 (2010).
48. Sandbo, N. et al. Delayed stress fiber formation mediates pulmonary myofibroblast differentiation in response to TGF-β. Am. J. Physiol. Lung Cell. Mol. Physiol. 301, L656-L666 (2011).
49. Thannickal, V. J. et al. Myofibroblast differentiation by transforming growth factor-β1 is dependent on cell adhesion and integrin signalling via focal adhesion kinase. J. Biol. Chem. 278, 12384-12389 (2003).
50. Iwaisako, K. et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor γ agonist. Proc. Natl Acad. Sci. USA 109, E1369-E1376 (2012).
51. Zeybel, M. et al. Multigenerational epigenetic adaption of the hepatic wound-healing response. Nat. Med. 18, 1369-1377 (2012).
52. Mann, J. et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 138, 705-714 (2010).
53. Kulkarni, A. A., Thatcher, T. H., Olsen, K. C., Maggirwar, S. B. & Phipps, R. P. PPAR-γ ligands repress TGF-β-induced myofibroblast differentiation by targeting the PI3k/Akt pathway: implications for therapy of fibrosis. PLoS ONE 6, 1-11 (2011).
54. Wei, J. et al. PPARγ downregulation by TGF β in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS ONE 5, 1-13 (2010).
55. Ratziu, V. et al. Long-term efficacy of rosiglitazone in non-alcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51, 445-453 (2010).
56. Belfort, R. et al. A placebo-controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis. N. Engl. J. Med. 355, 2297-2307 (2006).
57. Knight, S. D. et al. Discovery of GSK21246458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. Am. Chem. Soc. Chem. Lett. 1, 39-43 (2010).
58. Sabatini, D. M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6, 729-734 (2006).
59. Loewith, R. et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457-468 (2002).
60. Malouf, M. A., Hopkins, P. & Glanville, A. R. Everolimus in IPF study investigators. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology 16, 776-783 (2011).
61. Manley, P. W. et al. Imatinib: a selective tyrosine kinase inhibitor. Eur. J. Cancer 38, S19-S27 (2002).
62. Aono, Y. et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Crit. Care Med. 1 71, 1279-1285 (2005).
63. Daniels, C. E. et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am. J. Respir. Crit. Care Med. 181, 604-610 (2010).
64. Prey, S. et al. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br. J. Dermatol. 167, 1138-1144 (2012).
65. Richeldi, L. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2071-2082 (2014).
66. Fernandez-Fernandez, B., Ortiz, A., Gomez-Guerro, C. & Egido, J. Therapeutic approaches to diabetic nephropathy-beyond the RAS. Nat. Rev. Nephrol. 10, 325-346 (2014).
67. Alcorn, J. F. et al. C Jun N terminal kinase 1 is required for the development of pulmonary fibrosis. Am. J. Respir. Cell. Mol. Biol. 40, 422-432 (2009).
68. Callahan, J. F. et al. Identification of novel inhibitors of the transforming growth factor β1 (TGF-β1) type I receptor (ALK5). J. Med. Chem. 45, 999-1001 (2002).
69. Inman, G. J. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type 1 activin receptor-like kinase (ALK) receptors ALK4, ALK5 and ALK7. Mol. Pharmacol. 62, 65-74 (2002).
70. Anderton, M. J. et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol. Pathol. 39, 916-924 (2011).
71. Akhurst, R. J. & Hata, A. Targeting the TGF-β signalling pathway in disease. Nat. Rev. Drug Discov. 11, 790-811 (2012).
72. Bonniaud, P. Smad3 null mice develop airspace enlargement and are resistant to TGF-β-mediated pulmonary fibrosis. J. Immunol. 173, 2099-2108 (2004).
73. Sato, M., Muragaki, Y., Saika, S., Roberts, A. & Ooshima, A. Targeted disruption of TGF-β1/Smad3 signalling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest. 112, 1486-1494 (2003).
74. Munger, J. A. Huang, X. et al. The integrin αvβ6 binds and activates latent TGF-β1: a mechanism for regulating pulmonary fibrosis. Cell 96, 319-328 (1999).
75. Patsenker, E. et al. Inhibition of integrin αvβ6 on cholangiocytes blocks transforming growth factor b activation and retards biliary fibrosis progression. Gastroenterology 135, 660-670 (2008).
76. Henderson, N. C. et al. Targeting of av integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 19, 1617-1624 (2013).
77. Barry-Hamilton, V. et al. Allosteric inhibition of lysyl oxidase like 2 impedes the development of a pathologic microenvironment. Nat. Med. 16, 1009-1017 (2010).
78. Rodriguez, H. M. et al. Modulation of lysyl oxidase like 2 enzymatic activity by an allosteric antibody inhibitor. J. Biol. Chem. 285, 20964-20974 (2010).
79. Olsen, K. C. et al. Transglutaminase 2 and its role in pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 184, 699-707 (2011).
80. Johnson, T. S. et al. Tissue transglutaminase and the progression of human renal scarring. J. Am. Soc. Nephrol. 14, 2052-2062 (2003).
81. Telci, D., Collighan, R. J., Basaga, H. & Griffin, M. Increased TG2 expression can result in induction of transforming growth factor 1, causing increased synthesis and deposition of matrix proteins, which can be regulated by nitric oxide. J. Biol. Chem. 284, 29547-29558 (2009).
82. McKleroy, W., Lee, T.-H. & Atabai, K. Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 304, L709-L721 (2013).
83. Tang, X. et al. Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis. Am. J. Pathol. 183, 470-479 (2013).
84. Nakayama, S. et al. Pirfenidone inhibits the expression of HSP47 in TGF-β1-stimulated human lung fibroblasts. Life Sci. 82, 210-217 (2008).
85. Ziol, M. et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41, 48-54 (2005).
86. Hinz, B. Tissue stiffness, latent TGF-β1 activation and mechanical signal transduction: implications for the pathogenesis and treatment of fibrosis. Curr. Rheumatol. Rep. 11, 120-126 (2009).
87. Mih, J. D. et al. A multiwall platform for studying stiffness dependant cell biology. PLoS ONE 6, 1-10 (2011).
88. Liu, F. et al. Feedback amplification of fibrosis through matrix stiffening and COX 2 suppression. J. Cell Biol. 190, 693-706 (2010).
89. Olsen, A. L. et al. Hepatitic stellate cells require a stiff environment for myofibroblastic differentiation. Am. J. Physiol. Lung Cell. Mol. Physiol. 301, G110-G118 (2011).
90. Vittal, R. et al. Peptide-mediated inhibition of mitogen-activated protein kinase 2 ameliorates bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell. Mol. Biol. 49, 47-57 (2013).
91. Moeller, A., Ask, K., Warburton, D., Gauldie, J. & Kolb, M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int. J. Biochem. Cell Biol. 40, 362-382 (2008).
92. Edwards, A. M., Bountra, C, Kerr, D. J. & Willson, T. M. Open access chemical and clinical probes to support drug discovery. Nat. Chem. Biol. 5, 436-440 (2009).
93. Peters, J.-U. (Ed.) Polypharmacology in Drug Discovery (Wiley, 2012).
94. Morphy, J. R., Harris, J. C. (Eds) Designing multi-target drugs (RSC Publishing, 2012).
95. Morphy, R. & Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 48, 6523-6543 (2005).
96. Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S. & Sommergruber, W. BIBF-1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumour efficacy. Cancer Res. 68, 4774-4782 (2008).
97. Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690 (2008).
98. Dar, A. C, Das, T. K., Shokat, K. M. & Cagan, R. L Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 486, 80-84 (2012).
99. Besnard, J. Automated design of ligands to polypharmacological ligands. Nature 492, 215-220 (2011).
100. Moffat, J. G., Rudolph, J. & Bailey, D. Phenotypic screening in cancer drug discovery-past, present and future. Nat. Rev. Drug Discov. 13, 588-602 (2014).
101. Eggert, U. S. The why and how of phenotypic small molecule screens. Nat. Chem. Biol. 9, 206-209 (2013).
102. Swinney, D. C. & Anthony, J. How were new medicines discovered? Nat. Review Drug Discov. 10, 507-519 (2011).
103. 4 an adequate model of human cirrhosis? Hepatology 3, 112-120 (1983).
104. Constandinou, C, Henderson, N. & Iredale, J. P. Modeling liver fibrosis in rodents. Methods Mol. Med. 117, 237-250 (2005).
105. Crystal, R. G. et al. Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic and biochemical aspects. Ann. Intern. Med. 85, 769-788 (1976).
106. Shihab, F S., Bennett, W. M., Yi, H. & Andoh, T F. Pirfenidone treatment decreases transforming growth factor-p 1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am. J. Transplant. 2, 111-119 (2002).
107. Iyer, S. N., Gurujeyalakshmi, G. & Giri, S. N. Effects of pirfenidone on transforming growth factor-p gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 291, 367-373 (1999).
108. Nakazato, H., Oku, H., Yamane, S., Tsuruta, Y & Suzuki, R. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-a at the translational level. Eur. J. Pharmacol. 446, 177-185 (2002).
109. Oku, H., Nakazato, H., Horikawa, T., Tsuruta, Y. & Suzuki, R. Pirfenidone suppresses tumor necrosis factor-a, enhances interleukin 10 and protects mice from endotoxic shock. Eur. J. Pharmacol. 446, 167-176 (2002).
110. Seiwert, S. D., Kossen, K. & Serebryany, V. Method of modulating stress-activated protein kinase system. Patent WO2007062167A2 (2006).
111. Schaefer, C. J., Ruhrmund, D. W, Pan, L, Seiwert, S. D. & Kossen, K. Antifibrotic activities of pirfenidone in animal models. Eur. Respir. Rev. 20, 85-97 (2011).
112. Noble, P. W. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377, 1760-1769 (2011).
113. Wollin, L, Maillet, I., Quesniaux, V., Holweg, A. & Ryffel, B. Anti-fibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor, nintedanib, in experimental models of lung fibrosis. J. Pharmacol. Exp. Ther. 349, 209-220 (2014).
114. Wu, J., Luo, Y. & Zhou, T. Use of pyridone derivatives in the prevention or treatment of tissue or organ toxicity induced by cytotoxic agents and radiation. US Patent US20080161361A1 (2007).
115. Yi, X. Derivatives of pyridone and use thereof. US Patent US20110124872A1 (2010).
116. Burnier, M. Angiotensin II type 1 receptor blockers. Circulation 103, 904-912 (2001).
117. 4. World J. Gastroenterol. 6, 540-545 (2000).
118. Opgenorth, T. J. et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J. Pharmacol. Exp. Ther. 276, 473-481 (1996).
119. Feng, H. Q., Weymouth, N. D. & Rockey, D. C. Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G27-G33 (2009).
120. Kohan, D. E. et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J. Am. Soc. Nephrol. 22, 763-772 (2011).
121. Melvin Jr., L. S., Ullrich, M., Hege, H. G. & Weymann, J. Metabolites and derivatives of ambrisentan. US Patent US20100204163A1 (2008).
122. Uguccioni, M. et al. Endothelin 1 in idiopathic pulmonary fibrosis. J. Clin. Pathol. 48, 330-334 (1995).
123. Jain, R., Shaul, P. W., Borok, Z. & Willis, B. C. Endothelin 1 Induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-β1. Am. J. Respir. Cell. Mol. Biol. 37, 38-47 (2007).
124. Raghu, G. et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan. Ann. Intern. Med. 158, 641-649 (2013).
125. Clozel, M. et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270, 228-235 (1994).
126. Park, S. H., Saleh, D., Giaid, A. & Michel, R. P. Increased endothelin 1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am. J. Respir. Crit. Care Med. 156, 600-608 (1997).
127. Korn, J. H. et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 50, 3985-3993 (2004).
128. Seibold, J. R. et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum. 62, 2101-2108 (2010).
129. Samuni, Y., Goldstein, S., Dean, O. M. & Berk, M. The chemistry and biological activities of N-acetylcysteine. Biochim. Biophys. Acta 1830, 4117-4129 (2013).
130. Zafarullaha, M., Li, W. Q., Sylvestera, J. & Ahmad, M. Molecular mechanisms of N-acetylcysteine actions. Cell. Mol. Life Sci. 60, 6-20 (2003).
131. Jiang, J. X. et al. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic. Biol. Med. 53, 289-296 (2012).
132. Laleu, B. et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J. Med. Chem. 53, 7715-7730 (2010).
133. Jha, J. C. et al. Genetic targeting or pharmacologic inhibition of NADPH oxidase Nox4 provides renoprotection in long-term diabetic nephropathy. J. Am. Soc. Nephrol. 25, 1237-1254 (2014).
134. Hecker, L. et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci. Transl. Med. 6, 231ra47 (2014).
135. Aoyama, T. et al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 56, 2316-2327 (2012).
136. Reisman, S. A. et al. Bardoxolone methyl decreases megalin and activates Nrf2 in the kidney. J. Am. Soc. Nephrol. 23, 1663-1673 (2012).
137. Ahmad, R., Raina, D., Meyer, C., Kharbanda, S. & Kufe, D. Triterpenoid CDDO-Me blocks the NF-κB pathway by direct inhibition of IKKβ on Cys179. J. Biol. Chem. 281, 35764-35769 (2006).
138. Pergola, P. E. et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327-336 (2011).
139. Lind, U. et al. Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. J. Biol. Chem. 275, 19041-19049 (2000).
140. Shetlar, M.R., Shetlar, D.J., Bloom, R.F., Shetlar, C.L & Margolin, S.B. Involution of keloid implants in athymic mice treated with pirfenidone or with triamcinolone. J. Lab. Clin. Med. 132, 491-496 (1998).
141. Young, P. W. et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL 49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor y. J. Pharmacol. Exp. Ther. 284, 751-759 (1998).
142. Samah, M., El Aidy, Ael-R., Tawfik, M. K. &Ewais, M. M. S. Evaluation of the antifibrotic effect of fenofibrate and rosiglitazone on bleomycin-induced pulmonary fibrosis in rats. Eur. J. Pharmacol. 689, 186-193 (2012).
143. Cariou, B. et al. Dual peroxisome proliferator-activated receptor a/5 agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 36, 2923-2930 (2013).
144. Staels, B. et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor a/S agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 58, 1941-1952 (2013).
145. Jani, R. H., Kansagra, K., Jain, M. R. & Patel, H. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARa agonist with moderate PPARy agonist activity in healthy human subjects. Clin. Drug. Investig. 33, 809-816 (2013).
146. Henke, B. R. et al. N-(2 benzoylphenyl)-L-tyrosine PPARy agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem. 41, 5020-5036 (1998).
147. Kawaguchi, K. et al. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L amino acid-defined diet. Biochem. Biophys. Res. Commun. 31 5, 187-195 (2004).
148. Son, M. K. et al. HS-173, a novel PI3K inhibitor, attenuates the activation of hepatic stellate cells in liver fibrosis. Scientif. Rep. 3, 3470 (2013).
149. Sedrani, R., Cottens, S., Kallen, J. & Schuler, W. Chemical modification of rapamycin: the discovery of SDZ RAD Transplant. Proc. 30, 2192-2194 (1998).
150. März, A. M., Fabian, A. K., Kozany, C, Bracher, A. & Hausch, F Large FK506 binding proteins shape the pharmacology of rapamycin. Mol. Cell. Biol. 33, 1357-1367 (2013).
151. Korfhagen, T. R. et al. Rapamycin prevents transforming growth factor-a-induced pulmonary fibrosis. Am. J. Respir. Cell. Mol. Biol. 41, 562-572 (2009).
152. Wu, M. J. et al. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int. 69, 2029-2036 (2006).
153. Duveau, D. Y. et al. Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors. Bioorg. Med. Chem. Lett. 23, 682 (2013).
154. Weisberg, E. et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-141 (2005).
155. Liu, Y et al. Inhibition of PDGF, TGF-p, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist nilotinib. J. Hepatol. 55, 612-625 (2011).
156. Iyoda, M., Shibata, T., Hirai, Y, Kuno, Y & Akizawa, T. Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease. J. Am. Soc. Nephrol. 22, 1486-1496 (2011).
157. Rhee, C. K. et al. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. Respiration 82, 273-287 (2011).
158. Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004).
159. Wang, Y. et al. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J. Hepatol. 53, 132-144 (2010).
160. Chen, Y. L. et al. Sorafenib inhibits transforming growth factor p 1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology 53, 1708-1718 (2011).
161. Das, J. et al. 2-aminothiazole as a novel kinase inhibitor template. structure-activity relationship studies toward the discovery of n-(2-chloro-6 methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4 pyrimidinyl]amino)]-1, 3-thiazole-5 carboxamide (dasatinib, BMS 354825) as a potent pan-src kinase inhibitor. J. Med. Chem. 49, 6819 (2006).
162. Akhmetshina, A. et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB. 22, 2214-2222 (2008).
163. Fridman, J. S. et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J. Immunol. 184, 5298-5307 (2010).
164. Dees, C. et al. JAK 2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. Arthritis Rheum. 64, 3006-3015 (2012).
165. Mesa, R. A., Yasothan, U. & Kirkpatrick, P. Ruxolitinib. Nat. Rev. Drug Discov. 11, 103-104 (2012).
166. Krenitsky, V. P. et al. Discovery of CC 930, an orally active anti-fibrotic JNK inhibitor. Bioorg. Med. Chem. Lett. 22, 1433-1438 (2012).
167. Alcorn, J. F. et al. c Jun N terminal kinase 1 is required for the development of pulmonary fibrosis. Am. J. Respir. Cell. Mol. Biol. 40, 422-432 (2009).
168. Reich, N. et al. Jun N terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann. Rheum. Dis. 71, 737-745 (2012).
169. Ward, B. C. et al. Peptide inhibitors of MK2 show promise for inhibition of abdominal adhesions. J. Surg. Res. 169, e27-e36 (2011).
170. Xu, L. et al. MMI 0100 inhibits cardiac fibrosis in myocardial infarction by direct actions on cardiomyocytes and fibroblasts via MK2 inhibition. J. Mol. Cell. Cardiol. 77, 86-101 (2014).
171. Muto, A. et al. Inhibition of mitogen activated protein kinase activated protein kinase II with MMI 0100 reduces intimal hyperplasia ex vivo and in vivo. Vascul. Pharmacol. 56, 47-55 (2012).
172. Iglarz, M. et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 327, 736-745 (2008).
173. Iglarz, M. et al. Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 183, A6445 (2011).
174. Raghu, G. et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur. Respir. J. 42, 1622-1632 (2013).
175. Bunnage, M. E. et al. Discovery of potent and selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis. J. Med. Chem. 50, 6095-6103 (2007).
176. Knoerzer, D. et al. Inhibition of activated thrombin activatable fibrinolysis inhibitor (TAFI) demonstrates therapeutic efficacy in bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Crit. Care Med. 181, A2000 (2010).
177. Fujimoto, H. et al. Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis. Am. J. Pathol. 168, 1086-1096 (2006).
178. Wong, M. G. et al. Cation-independent mannose-6-phosphate receptor inhibitor (PXS25) inhibits fibrosis in human proximal tubular cells by inhibiting conversion of latent to active TGF-β1. Am. J. Physiol. Renal. Physiol. 301, F84-F93 (2011).
179. Maldonado, F., Kottom, T. J. & Limper, A. H. PXS-25, a mannose-6-phosphate derivative, is effective in decreasing the production of extracellular matrix by TGF-β stimulated fibroblasts. Am. J. Respir. Crit. Care. Med. 179, A3471 (2009).
180. Pasquinelli, C. Safety and efficacy of a lysophosphatidic acid receptor antagonist (BMS 986020) in idiopathic pulmonary fibrosis. Pulmonary Fibrosis Foundation Summit [online] http://www.pffsummit.org/assets/pro- sat-1500-bms-ppt.pdf (2013)
181. Swaney, J. S. et al. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br. J. Pharmacol. 160, 1699-1713 (2010).
182. Tager, A. M. et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med. 14, 45-54 (2008).
183. Schaefer, M. et al. Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals. Patent WO2009135590A1 (2009).
184. Illiano, S. et al. Protective effect of LPA1 and 3 receptor antagonism in experimental skin fibrosis is linked to LPA activity in dermal fibroblasts of SSc patients. Ann. Rheum. Dis. 72, 129 (2013).
185. Sampaio, E. P. et al. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J. Exp. Med. 173, 699-703 (1991).
186. Tabata, C. et al. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J. Immunol. 179, 708-714 (2007).
187. Choe, J. Y. et al. Anti-fibrotic effect of thalidomide through inhibiting TGF-β-induced ERK1/2 pathways in bleomycin-induced lung fibrosis in mice. Inflamm. Res. 59, 177-188 (2010).
188. Ruchelman, A. L. et al. Isosteric analogs of lenalidomide and pomalidomide: synthesis and biological activity. Bioorg. Med. Chem. Lett. 23, 360-365 (2013).
189. Weingärtner, S. et al. Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. Ann. Rheum. Dis. 71, 1895-1899 (2012).
190. Holsinger, L. J. et al. Efficacy of a reversible cathepsin B inhibitor in a rodent model of liver fibrosis and human pharmacokinetic profile (Poster). AASLD Annual Meeting [online] http://www.virobayinc.com/docs/AASLD-Poster-2010.pdf (2010).
191. Holsinger, L. Inhibitors of cathepsin B. Patent WO2009100225A1 (2009).
192. Linton, S. D. et al. First in class pan caspase inhibitor developed for the treatment of liver disease. J. Med. Chem. 48, 6779-6782 (2005).
193. Canbay, A. et al. The caspase inhibitor IDN 6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J. Pharmacol. Exp. Ther. 308, 1191-1196 (2004).
194. Murphy, M. P. & Smith, R. A. J. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol. 47, 629-656 (2007).
195. +/-AkitaJ mice by the mitochondria-targeted therapy MitoQ. Biochem. J. 432, 9-19 (2010).
196. Kiriyama, M. et al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 122, 217-224 (1997).
197. Takenaka, M. et al. Effect of beraprost sodium (BPS) in a new rat partial unilateral ureteral obstruction model. Prostaglandins Leukot. Essent. Fatty Acids 80, 263-267 (2009).
198. Whittle, B. J., Silverstein, A. M., Mottola, D. M. & Clapp, L. H. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist. Biochem. Pharmacol. 84, 68-75 (2012).
199. Stratton, R. et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J. Clin. Invest. 10 8, 241-250 (2001).
200. Zhu, Y. et al. A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice. Respir. Res. 11, 34 (2010).
201. Chung, L. & Fiorentino, D. A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. J. Am. Acad. Dermatol. 54, 880-882 (2006).
202. Ezquerro, I. J. et al. A synthetic peptide from transforming growth factor β type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine 22, 12-20 (2003).
203. Hermida, N. et al. A synthetic peptide from transforming growth factor-β1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc. Res. 81, 601-609 (2009).
204. Santiago, B. et al. Topical application of a peptide inhibitor of transforming growth factor-β1 ameliorates bleomycin-induced skin fibrosis. J. Invest. Dermatol. 125, 450-455 (2005).
205. Björk, P. et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline 3-carboxamides. PLoS Biol. 7, e97 (2009).
206. Hesselstrand, R. et al. An open-label study to evaluate biomarkers and safety in systemic sclerosis (SSc) patients treated with paquinimod (ABR 215757). Ann. Rheum. Dis. 73 (Suppl. 2), 566-567 (2014).
207. Stenström, M. et al. Paquinimod (ABR 215757), an immunomodulatory compound, reduces fibrosis in the tight skin 1 (TSK 1) model for systemic sclerosis. Ann. Rheum. Dis. 73 (Suppl. 2), 574 (2014).
208. Pellicciari, R. et al. 6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45, 3569-3572 (2002).
209. Mudaliar, S. et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574-582 (2013).
210. Wang, X. X. et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am. J. Physiol. Renal Physiol. 297, 1587-1596 (2009).
211. Hambruch, E. et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. J. Pharmacol. Exp. Ther. 343, 556-567 (2012).
212. Lu, S. C. S. Adenosylmethionine. Int. J. Biochem. Cell Biol. 32, 391-395 (2000).
213. Corrales, F. et al. S-adenosylmethionine treatment prevents carbon tetrachloride-induced S-adenosyl-methionine synthetase inactivation and attenuates liver injury. Hepatology 16, 1022-1027 (1992).
214. Nieto, N. & Cederbaum, A. I. S-adenosylmethionine blocks collagen 1 production by preventing transforming growth factor β induction of the COL1A2 promoter. J. Biol. Chem. 280, 30963-30974 (2005).
215. Katsnelson, A. Heavy drugs draw heavy interest from pharma backers. Nat. Med. 19, 656 (2013).
216. Aslanian, A., Hogan, K., West, K., Bridson, G. W. & Wu, L. CTP-499, a novel drug for the treatment of chronic kidney disease, ameliorates renal fibrosis and inflammation in vivo (Poster). J. Am. Soc. Nephrol. 23 (Suppl. 1) (2012).
217. Onorato, J. M., Jenkins, A. J., Thorpe, S. R. & Baynes, J. W. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. J. Biol. Chem. 275, 21177-21184 (2000).
218. Voziyan, P. A., Metz, T. O., Baynes, J. W. & Hudson, B. G. A post-amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J. Biol. Chem. 277, 3397-3403 (2002).
219. Williams, M. E. et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am. J. Nephrol. 27, 605-614 (2007).
220. Degenhardt, T. P. et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 61, 939-950 (2002).
221. Marquardt, D. et al. Tocopherol activity correlates with its location in a membrane: a new perspective on the antioxidant vitamin E. J. Am. Chem. Soc. 135, 7523-7533 (2013).
222. Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675-1685 (2010).
223. Mirolo, M. et al. Impact of the anti-inflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte chemotactic proteins. Eur. Cytokine Netw. 19, 119-122 (2008).
224. Zhu, X. Y. et al. The chemokine monocyte chemoattractant protein 1 contributes to renal dysfunction in swine renovascular hypertension. J. Hypertens. 27, 2063-2073 (2009).
225. Dorr, P. et al. Maraviroc (UK 427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721-4732 (2005).
226. Ochoa-Callejero, L. et al. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS ONE 8, e53992 (2013).
227. Pérez-Martínez, L. et al. Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). J. Antimicrob. Chemother. 69, 1903-1910 (2014).
228. Mirzadegan, T. et al. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists. J. Biol. Chem. 275, 25562-25571 (2000).
229. Kitagawa, K. et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am. J. Path. 165, 237-246 (2004).
230. Ishizaki, T. et al. Pharmacological properties of Y-27632, a specific inhibitor of RHO-associated kinases. Am. Soc. Pharmacol. Exp. Ther. 57, 976-983 (2000).
231. Nagatoya, K. et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int. 61, 1684-1695 (2002).
232. Tada, S. et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J. Hepatol. 34, 529-536 (2001).
233. Ma, W. W. Development of focal adhesion kinase inhibitors in cancer therapy. Anticancer Agents Med. Chem. 11, 638-642 (2011).
234. Lagares, D. et al. Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation. Arthritis Rheum. 64 1653-1664 (2012).
235. Mori, Y. et al. Selective inhibition of activin receptorlike kinase 5 signaling blocks profibrotic transforming growth factor p responses in skin fibroblasts. Arthritis Rheum. 50, 4008-4021 (2004).
236. Jinnin, M., Ihn, H. & Tamaki, K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-p 1 induced extracellular matrix expression. Mol. Pharmacol. 69, 597-607 (2006).
237. Li, J. et al. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes 59, 2612-2624 (2010).
238. Reed, N. I. et al. The avp1 integrin plays a critical in vivo role in tissue fibrosis. Sci. Transl. Med. 7, 288ra79 (2015).
239. Munger, J. S., Harpel, J. G., Giancotti, F. G. & Rifkin, D. B. Interactions between growth factors and integrins: Latent forms of transforming growth factor-p are ligands for the integrin avp 1. Mol. Biol. Cell 9, 2627-2638 (1998).
240. Riley, D. J. et al. p-aminopropionitrile prevents bleomycin-induced pulmonary fibrosis in the hamster. Am. Rev. Respir. Dis. 125, 67-73 (1982).
241. Johnson, T. S. et al. Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. J. Am. Soc. Nephrol. 18, 3078-3088 (2007).
242. Huang, L. et al. Transglutaminase inhibition ameliorates experimental diabetic nephropathy Kidney Int. 76, 383-394 (2009).
243. Bickel, M. et al. Beneficial effects of inhibitors of prolyl 4 hydroxylase in carbon tetrachloride-induced fibrosis of the liver in rats. J. Hepatol. 13, S26-S34 (1991).
244. Sakaida, I. et al. The prolyl 4 hydroxylase inhibitor HOE 077 prevents activation of ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline-deficient L amino acid-defined diet. Hepatology 23, 755-763 (1996).
245. Matsumura, Y. et al. Prolyl 4-hydroxylase inhibitor (HOE 077) inhibits pig serum-induced rat liver fibrosis by preventing stellate cell activation. J. Hepatol. 27, 185-192 (1997).
246. Fish, P. V. et al. Potent and selective nonpeptidic inhibitors of procollagen C proteinase. J. Med. Chem. 50, 3442-3456 (2007).
247. Ahn, H. S. et al. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1 methylethyl) phenyl]methyl]-7H-pyrrolo[3, 2 f]quinazoline-1, 3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem. Pharmacol. 60, 1425-1434 (2000).
248. Sonin, D. L. et al. Protease-activated receptor 1 inhibition by SCH79797 attenuates left ventricular remodeling and profibrotic activities of cardiac fibroblasts. J. Cardiovasc. Pharmacol. Ther. 18, 460-475 (2013).
249. Izuhara, Y. et al. A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J. Cereb. Blood Flow Metab. 30, 904-912 (2010).
250. Huang, W. T. et al. Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis. Am. J. Respir. Cell. Mol. Biol. 46, 87-95 (2012).
251. Kawabata, K. et al. ONO 5046, a novel inhibitor of human neutrophil elastase. Biochem. Biophys. Res. Commun. 177, 814-820 (1991).
252. Taooka, Y. et al. Effects of neutrophil elastase inhibitor on bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Crit. Care Med. 156, 260-265 (1997).
253. Takemasa, A., Ishii, Y. & Fukuda, T. A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice. Eur. Respir. J. 40, 1475-1482 (2012).
254. McGaha, T. L., Phelps, R. G., Spiera, H. & Bona, C. Halofuginone, an inhibitor of type 1 collagen synthesis and skin sclerosis, blocks transforming-growth-factor-β-mediated Smad3 activation in fibroblasts. J. Invest. Dermatol. 118, 461-470 (2002).
255. Keller, T. L. et al. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat. Chem. Biol. 8, 311-317 (2012).
256. Sundrud, M. S. et al. Halofuginone inhibits Th17 cell differentiation by activating the amino acid starvation response. Science 324, 1334 (2009).
257. Bruck, R. et al. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 33, 379-386 (2001).
258. Nagler, A. et al. Reduction in pulmonary fibrosis in vivo by halofuginone. Am. J. Respir. Crit. Care. Med. 154, 1082-1086 (1996).
259. Zhang, W. b. et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40 4C are weak partial agonists. J. Biol. Chem. 277, 24515-24521 (2002).
260. Song, J. S. et al. Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. Exp. Mol. Med. 42, 465-476 (2010).
261. Makino, H. et al. Antifibrotic effects of CXCR4 antagonist in bleomycin-induced pulmonary fibrosis in mice. J. Med. Invest. 60, 127-137 (2013).
262. Kliewer, S. A. et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92, 73-82 (1998).
263. Marek, C. J. et al. Pregnenolone 16α carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms. Biochem. J. 387, 601-608 (2005).
264. Brinkmann, V. et al. The immune modulator FTY720 targets sphingosine 1 phosphate receptors. J. Biol. Chem. 277, 21453-21457 (2002).
265. Krämer, S. et al. The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy. Am. J. Physiol. Renal Physiol. 297, F218-F227 (2009).
266. Brunati, A. M. et al. Cross-talk between PDGF and S1P signalling elucidates the inhibitory effect and potential antifibrotic action of the immunomodulator FTY720 in activated HSC-cultures. Biochim. Biophys. Acta. 1783, 347-359 (2008).
267. Huang, S. M. A. et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614-620 (2009).
268. Distler, A. et al. Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling. Ann. Rheum. Dis. 72, 1575-1580 (2013).
269. Eguchi, M., Nguyen, C., Lee, S. C. & Kahn, M. ICG-001, a novel small molecule regulator of TCF/β-catenin transcription. Med. Chem. 1, 467-472 (2005).
270. Henderson, W. R. et al. Inhibition of Wnt/β catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc. Natl Acad. Sci. USA 107, 14309-14314 (2010).
271. Beyer, C. et al. Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. Ann. Rheum. Dis. 72, 1255-1258 (2013).
272. Abramovitz, M. et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta 1483, 285-293 (2000).
273. Huang, S. et al. Prostaglandin E2 inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signalling. Am. J. Physiol. Lung Cell Mol. Physiol. 292, L405-L413 (2007).
274. Griffin, B. W., Klimko, P., Crider, J. Y. & Sharif, N. AAL-8810: a novel prostaglandin F2a analog with selective antagonist effects at the prostaglandin F2a (FP) receptor. J. Pharmacol. Exp. Ther. 290, 1278-1284 (1999).
275. Ding, W. y. et al. Prostaglandin F2a facilitates collagen synthesis in cardiac fibroblasts via an F prostanoid receptor/protein kinase C/Rho kinase pathway independent of transforming growth factor p 1. Int. J. Biochem. Cell Biol. 44, 1031-1039 (2012).
276. Nelson, D. W. et al. Structure-activity relationship studies on a series of novel, substituted 1 benzyl-5 phenyltetrazole P2X7 antagonists. J. Med. Chem. 49, 3659-3666 (2006).
277. Donnelly-Roberts, D. L. & Jarvis, M. F Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br. J. Pharmacol. 151, 571-579 (2007).
278. Ji, X. et al. P2X7 receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertens. Res. 35, 173-179 (2012).
279. Wulff, H. et al. Design of a potent and selective inhibitor of the intermediate-conductance Ca21 activated K1 channel, IKCa1: a potential immunosuppressant. Proc. Natl Acad. Sci. USA 97, 8151-8156 (2000).
280. Grgic, I. et al. Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc. Natl Acad. Sci. USA 106, 14518-14523 (2009).
281. Huang, C. et al. Blockade of KCa3.1 ameliorates renal fibrosis through the TGF-p 1/Smad pathway in diabetic mice. Diabetes 62, 2923-2934 (2013).
282. 2+ channels. Br. J. Pharmacol. 143, 1050-1057 (2004).
283. Sugano, N. et al. T type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int. 73, 826-834 (2008).
284. Thomson, C. A., Atkinson, H. M. & Ananthanarayanan, V. S. Identification of small molecule chemical inhibitors of the collagen-specific chaperone Hsp47. J. Med. Chem. 48, 1680-1684 (2005).
285. Xia, Z. et al. Suppression of renal tubulointerstitial fibrosis by small interfering RNA targeting heat shock protein 47. Am. J. Nephrol. 28, 34-46 (2008).
286. MacKinnon, A. C. et al. Regulation of transforming growth factor-p 1-driven lung fibrosis by galectin 3. Am. J. Respir. Crit. Care Med. 185, 537-546 (2012).
287. Shen, G. X. Selective protein kinase C inhibitors and their applications. Curr. Drug Targets Cardiovasc. Haematol. Disord. 3, 301-307 (2003).
288. Lee, S. J. et al. PKC5 as a regulator for TGFp1 induced cc-SMA production in a murine nonalcoholic steatohepatitis model. PLoS ONE 8, e55979 (2013).
289. Underwood, D. C. et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. J. Physiol. Lung Cell Mol. Physiol. 279, L895-L902 (2000).
290. Patchett, A. A. et al. A new class of angiotensin-converting enzyme inhibitors. Nature 288, 280-283 (1980).
291. Kaneto, H. et al. Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kidney Int. 45, 1637-1647 (1994).
292. 2C receptor subtypes by molecular modelling. Life Sci. 73, 193-207 (2003).
293. 2A receptor antagonists inhibit hepatic stellate cell activation and facilitate apoptosis. Liver Int. 33, 535-543 (2013).
294. Hamasaki, Y. et al. A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1. Am. J. Physiol. Renal Physiol. 305, F1796-F1803 (2013).
295. Jiang, G., Madan, D. & Prestwich, G. D. Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin. Bioorg. Med. Chem. Lett. 21, 5098-5101 (2011).
296. Oikonomou, N. et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am. J. Respir. Cell. Mol. Biol. 47, 566-574 (2012).
297. Xiao, J. et al. Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1. Nat. Commun. 4, 1953 (2013).
298. Pini, A. et al. Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity. J. Pharmacol. Exp. Ther. 335, 589-599 (2010).
299. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
300. Tang, X. et al. BET bromodomain proteins mediate downstream signaling events following growth factor stimulation in human lung fibroblasts and are involved in bleomycin-induced pulmonary fibrosis. Mol. Pharmacol. 83, 283-293 (2013).
301. 4: structure-function relationships. Biochem. Biophys. Res. Commun. 180, 1416-1421 (1991).
302. Zhou, X. Y. et al. BML-11, a lipoxin receptor agonist, protected carbon tetrachloride-induced hepatic fibrosis in rats. Inflammation 36, 1101-1106 (2013).
303. Zhan, Y. et al. Cytosporone B is an agonist for nuclear orphan receptor Nur77. Nat. Chem. Biol. 4, 548-556 (2008).
304. Palumbo-Zerr, K. et al. Orphan nuclear receptor NR4A1 regulates transforming growth factor-ß signaling and fibrosis. Nat. Med. 21, 150-158 (2015).